Background: Thrombolytic therapy with urokinase 5000 units has been the standard therapy for the restoration of thrombosed central catheters. However, with the decreased availability of urokinase, alternatives needed to be sought. The aim of the study was to determine the efficacy, bioactivity, dwell time and cost of cryopreserved recombinant tissue plasminogen activator (rTPA) in the restoration of occluded central venous access devices.

Materials And Methods: For children < 10 kg, a dose of 0.5 mg, and for children >10 kg, a dose of 1mg was used. The dwell time was 1-2 hours.

Results: Of the 40 courses of rTPA, 39 fully restored central venous line patency (97%). Successful courses were instilled for an average of 1 hour.

Conclusion: Cryopreserved rTPA appears to be safe and effective in the dose used to restore the patency of occluded central venous access devices in pediatric oncology patients.

Download full-text PDF

Source
http://dx.doi.org/10.5144/0256-4947.2002.300DOI Listing

Publication Analysis

Top Keywords

central venous
16
occluded central
12
venous access
12
cryopreserved recombinant
8
recombinant tissue
8
tissue plasminogen
8
plasminogen activator
8
restoration occluded
8
access devices
8
devices pediatric
8

Similar Publications

Objective: Superior vena cava syndrome (SVC) is a debilitating disease, and surgical reconstruction has been described with some of the best results using spiral great saphenous vein (SGSV) grafts. SGSV grafts can be difficult to construct, and a long segment of saphenous vein is needed. Femoral vein has been an excellent conduit for infected aortic and peripheral reconstructions in our hands, and we sought to review outcomes using this conduit for SVC reconstruction.

View Article and Find Full Text PDF

Background: Central venous catheters (CVCs) are placed where the vena cava meets the right atrium. Their common use raises the risk of catheter-related thrombosis (CRT), a potentially life-threatening complication.

Aim: This study leverages machine learning to develop a CRT predictive model for abdominal surgery patients, aiming to refine clinical decisions and elevate treatment quality.

View Article and Find Full Text PDF

Apheresis is essential to conducting hematopoietic cell transplantation and genetically engineered cellular therapy procedures. Many patients and donors require central venous catheter (CVC) access for apheresis due to lack of adequate peripheral venous access. CVC placement has risks of associated complications and requires additional institutional resources and expertise.

View Article and Find Full Text PDF

Objective: This review aimed to examine if there is any difference in the risk of thrombosis and central line-associated bloodstream infection (CLABSI) with the use of peripherally inserted central catheter (PICC) and conventional central venous catheters (CVC) in hematological cancer patients.

Methods: We searched the online databases of PubMed, CENTRAL, Scopus, Web of Science, and Embase for all types of studies comparing the risk of thrombosis and CLABSI between PICC and CVC. The search ended on 23rd September 2024.

View Article and Find Full Text PDF

Central Venous Catheter-associated Venous Thrombosis in Neonates: "Seek and You Shall Find".

Anesthesiology

February 2025

Department of Anaesthesia and Pain Management, The Royal Children's Hospital, Melbourne, Australia; Department of Paediatrics, The University of Melbourne, Melbourne, Australia; Anaesthesia Research Group and Haematology Research Group, Murdoch Children's Research Institute, Melbourne, Australia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!